Literature DB >> 20682181

IL-23: a promising therapeutic target for systemic lupus erythematosus.

Rui-Xue Leng1, Hai-Feng Pan, Gui-Mei Chen, Chao Wang, Wei-Zi Qin, Li-Li Chen, Jin-Hui Tao, Dong-Qing Ye.   

Abstract

Cytokine-mediated immunity plays a crucial role in the pathogenesis of various autoimmune diseases including systemic lupus erythematosus (SLE). The recent identification of the dimeric interleukin (IL)-12-related cytokine IL-23 now contributes to our understanding of the fine-tuning of cellular immunity. The critical implication of IL-12 p40 in autoimmune inflammation has long been misinterpreted and until recently have studies revealed that it is IL-23, not IL-12, is the crucial factor in this immune dysregulation. Therefore, targeting of IL-23 or the IL-23 receptor is a potential therapeutic approach for autoimmune diseases including SLE. In this opinion article, we will discuss the biological features of IL-23 and summarize recent advances on the role of IL-23 in the pathogenesis and treatment of SLE. Copyright 2010 IMSS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20682181     DOI: 10.1016/j.arcmed.2010.02.011

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  9 in total

Review 1.  T cells and IL-17 in lupus nephritis.

Authors:  Tomohiro Koga; Kunihiro Ichinose; George C Tsokos
Journal:  Clin Immunol       Date:  2016-04-21       Impact factor: 3.969

Review 2.  Interleukin-35: a Potential Therapeutic Agent for Autoimmune Diseases.

Authors:  Shi-Yang Guan; Rui-Xue Leng; Muhammad Imran Khan; Humera Qureshi; Xiang-Pei Li; Dong-Qing Ye; Hai-Feng Pan
Journal:  Inflammation       Date:  2017-02       Impact factor: 4.092

3.  Evaluation of circulating endothelial biomarkers in familial Mediterranean fever.

Authors:  Baris Onder Pamuk; Ismail Sari; Sema Selcuk; Goksel Gokce; Didem Leyla Kozaci
Journal:  Rheumatol Int       Date:  2013-01-29       Impact factor: 2.631

Review 4.  The Potential of Harnessing IL-2-Mediated Immunosuppression to Prevent Pathogenic B Cell Responses.

Authors:  Amber Papillion; André Ballesteros-Tato
Journal:  Front Immunol       Date:  2021-04-27       Impact factor: 7.561

5.  Expression of IL-17, IL-23 and their receptors in minor salivary glands of patients with primary Sjögren's syndrome.

Authors:  Diana Mieliauskaite; Irena Dumalakiene; Rita Rugiene; Zygmunt Mackiewicz
Journal:  Clin Dev Immunol       Date:  2012-01-03

6.  Cytokine and autoantibody clusters interaction in systemic lupus erythematosus.

Authors:  Yovana Pacheco; Julián Barahona-Correa; Diana M Monsalve; Yeny Acosta-Ampudia; Manuel Rojas; Yhojan Rodríguez; Juliana Saavedra; Mónica Rodríguez-Jiménez; Rubén D Mantilla; Carolina Ramírez-Santana; Nicolás Molano-González; Juan-Manuel Anaya
Journal:  J Transl Med       Date:  2017-11-25       Impact factor: 5.531

Review 7.  Virgin Olive Oil and Health: Summary of the III International Conference on Virgin Olive Oil and Health Consensus Report, JAEN (Spain) 2018.

Authors:  José J Gaforio; Francesco Visioli; Catalina Alarcón-de-la-Lastra; Olga Castañer; Miguel Delgado-Rodríguez; Monserrat Fitó; Antonio F Hernández; Jesús R Huertas; Miguel A Martínez-González; Javier A Menendez; Jesús de la Osada; Angeliki Papadaki; Tesifón Parrón; Jorge E Pereira; María A Rosillo; Cristina Sánchez-Quesada; Lukas Schwingshackl; Estefanía Toledo; Aristidis M Tsatsakis
Journal:  Nutrients       Date:  2019-09-01       Impact factor: 5.717

Review 8.  Current Insights and Future Prospects for Targeting IL-17 to Treat Patients With Systemic Lupus Erythematosus.

Authors:  Tomohiro Koga; Kunihiro Ichinose; Atsushi Kawakami; George C Tsokos
Journal:  Front Immunol       Date:  2021-02-01       Impact factor: 7.561

Review 9.  The regulatory mechanism and potential application of IL-23 in autoimmune diseases.

Authors:  De-Kai Xiong; Xiang Shi; Miao-Miao Han; Xing-Min Zhang; Na-Na Wu; Xiu-Yue Sheng; Ji-Nian Wang
Journal:  Front Pharmacol       Date:  2022-09-13       Impact factor: 5.988

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.